Healthcare Active Runners: Pfizer Inc. (NYSE:PFE), Gilead Sciences, (NASDAQ:GILD), United Health Group (NYSE:UNH), Merck & Co. (NYSE:MRK)

Analysts at Jefferies Group cut their price target on shares of Pfizer (NYSE:PFE) to $36.00 in a research report issued to clients and investors on Monday, Analyst Ratings.Net reports. The firm currently has a “buy” rating on the stock. Jefferies Group’s target price indicates a potential upside of 20.56% from the stock’s previous close. Pfizer Inc. (NYSE:PFE) shares after opening at $30.15 moved to $30.40 on last trade day and at the end of the day closed at $1111. Company price to sales ratio in past twelve months was calculated as 3.75 and price to cash ratio as 5.97. Pfizer Inc. (NYSE:PFE) showed a negative weekly performance of -1.18%.

Gilead Sciences (NASDAQ:GILD) EVP Norbert Bischofberger sold 90,000 shares of Gilead Sciences stock on the open market in a transaction that occurred on Monday, April 14th. The stock was sold at an average price of $67.03, for a total transaction of $6,032,700.00. Following the completion of the transaction, the executive vice president now directly owns 119,302 shares of the company’s stock, valued at approximately $7,996,813.Gilead Sciences, Inc. (NASDAQ:GILD) shares advanced 1.04% in last trading session and ended the day on $70.00. GILD return on equity ratio is recorded as 28.30% and its return on assets is 13.70%. Gilead Sciences, Inc. (NASDAQ:GILD) yearly performance is 37.63%.

UnitedHealth Group (NYSE:UNH)‘s stock had its “hold” rating reiterated by research analysts at Cantor Fitzgerald in a report released on Tuesday, American Banking News.com reports. They currently have a $80.00 price target on the stock. Cantor Fitzgerald’s price objective points to a potential upside of 2.31% from the stock’s previous close. United Health Group Inc. (NYSE:UNH) shares moved down -3.08% in last trading session and was closed at $75.78, while trading in range of $ 73.61 – 76.65. United Health Group Inc. (NYSE:UNH) year to date (YTD) performance is 1.00%.

Equities research analysts at Jefferies Group boosted their price objective on shares of Merck & Co. (NYSE:MRK) to $61.00 in a research note issued to investors on Monday, Analyst Ratings Network reports. The firm currently has a “hold” rating on the stock. Jefferies Group’s price target would indicate a potential upside of 8.21% from the stock’s previous close. Merck & Co., Inc. (NYSE:MRK) weekly performance is 1.11%. On last trading day company shares ended up $56.47. Merck & Co., Inc. (NYSE:MRK) distance from 50-day simple moving average (SMA50) is 1.43%. Analysts mean target price for the company is $57.11.